Neurotech International Limited announced strategic cultivation partnership with CannaPacific Limited ("CannaPacific") to grow and maintain genetic stock and assist in the development of elite varietal strains developed by NTI and Dolce Cann through their exclusive Licensing agreement. Following successful outcome of the Phase I/II clinical trials starting this quarter, the partnership enables NTI to prepare for expanded clinical studies in larger patient groups moving into calendar Second Quarter and Third Quarter as the current trial parameters are intended to form the basis for larger future studies which will assess the efficacy of these strains in a broader patient population in respect of autism and related neurological disorders. CannaPacific will house the genetic stock and assist in the development of NTI's exclusively licensed Dolce varietal strains within CannaPacific's orthern NSW cultivation facility. CannaPacific is licenced and permitted by the Australian Government (Office of Drug Control) to cultivate and research medicinal cannabis which is a requirement to commence sales under the TGA Special Access Scheme. The agreement between Neurotech and CannaPacific is for an initial period to 30 June 2021 and does not contain provision for termination prior to this date and is subject to mutual due diligence and the receipt of all relevant regulatory approvals. As part of the fees payable, CannaPacific is to be issued 1,000,000 fully paid ordinary shares in the Company upon receipt of an Office of Drug Control permit to produce NTI /Dolce cannabis strains for clinical trials, and a further 1,000,000 fully paid ordinary shares in the Company within five business days of the delivery of the first harvest of dried flower to the Company, or by 1 August 2021 whichever occurs first.